[go: up one dir, main page]

LT2002035A - Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip moterų kontraceptikų komponentas - Google Patents

Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip moterų kontraceptikų komponentas

Info

Publication number
LT2002035A
LT2002035A LT2002035A LT2002035A LT2002035A LT 2002035 A LT2002035 A LT 2002035A LT 2002035 A LT2002035 A LT 2002035A LT 2002035 A LT2002035 A LT 2002035A LT 2002035 A LT2002035 A LT 2002035A
Authority
LT
Lithuania
Prior art keywords
mesoprogestins
female
progesterone receptor
component
receptor modulators
Prior art date
Application number
LT2002035A
Other languages
English (en)
Other versions
LT5001B (lt
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of LT2002035A publication Critical patent/LT2002035A/lt
Publication of LT5001B publication Critical patent/LT5001B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Šis išradimas yra susijęs su mezoprogestinų panaudojimu medikamento moterų kontracepcijai gamyboje, su farmaciniu preparatu moterų kontracepcijai, įvedant efektyvius kiekius mezoprogestino moteriai, kuri nori išvengti pastojimo. Esant reikalui, mezoprogestinas gali būti naudojamas derinyje su estrogenu. Mezoprogestinais yra vadinami junginiai, kurie turi ir agonistinį, ir antagonistinį poveikį į progesterono receptorių (PR) in vivo. Jie stabilizuoja PR funkciją tarpiniame lygmenyje tarp agonistinio ir antagonistinio lygmens. Atitinkamų funkcinių būsenų negalima pasiekti naudojant progestinus arba antiprogestinus. Pagal šį išradimą tinkamiausiais mezoprogestinais yra J867, J912, J956 ir J1042.
LT2002035A 1999-08-31 2002-03-26 Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip moterų kontraceptikų komponentas LT5001B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31

Publications (2)

Publication Number Publication Date
LT2002035A true LT2002035A (lt) 2002-10-25
LT5001B LT5001B (lt) 2003-03-25

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2002035A LT5001B (lt) 1999-08-31 2002-03-26 Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip moterų kontraceptikų komponentas

Country Status (28)

Country Link
EP (1) EP1605949A2 (lt)
JP (1) JP2003511399A (lt)
KR (1) KR20020038745A (lt)
CN (1) CN1384748A (lt)
AR (1) AR025455A1 (lt)
AU (1) AU781835B2 (lt)
BG (1) BG106441A (lt)
BR (1) BR0013711A (lt)
CA (1) CA2383650A1 (lt)
CO (1) CO5190694A1 (lt)
CZ (1) CZ2002707A3 (lt)
EA (1) EA006805B1 (lt)
EE (1) EE200200103A (lt)
HR (1) HRP20020265A2 (lt)
HU (1) HUP0202515A3 (lt)
IL (1) IL148415A0 (lt)
LT (1) LT5001B (lt)
LV (1) LV12940B (lt)
MX (1) MXPA02002186A (lt)
NO (1) NO20020998L (lt)
NZ (1) NZ517470A (lt)
PE (1) PE20010579A1 (lt)
PL (1) PL353994A1 (lt)
SI (1) SI20853A (lt)
SK (1) SK2982002A3 (lt)
UA (1) UA77150C2 (lt)
WO (1) WO2001026603A2 (lt)
YU (1) YU13902A (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
ATE338763T1 (de) * 2002-08-02 2006-09-15 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
JP2006525358A (ja) * 2003-05-02 2006-11-09 ドゥラメド ファーマシューティカルズ， インコーポレイテッド 長期周期避妊養生法を利用するホルモン治療の方法
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
AU2005269938A1 (en) * 2004-07-07 2006-02-09 Wyeth Cyclic progestin regimens and kits
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
ME02548B (me) 2009-04-14 2017-02-20 Hra Pharma Lab Postupak za kontracepciju po potrebi
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (de) 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (de) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
ATE209919T1 (de) * 1987-09-24 2001-12-15 Jencap Res Ltd Oestrogen und progestin enthaltende verhütungspackungen
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4447715C2 (de) 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Behandlung von Prostatakarzinomen
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP0787002B1 (de) * 1994-10-24 2006-12-13 Schering Aktiengesellschaft Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
CA2255863A1 (en) * 1996-06-25 1997-12-31 Akzo Nobel Nv Progestogen-anti-progestogen regimens
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
HK1043788A1 (zh) * 1999-05-04 2002-09-27 American Home Products Corporation 四環黃體酮受體調節劑化合物及方法

Also Published As

Publication number Publication date
PL353994A1 (en) 2003-12-15
CO5190694A1 (es) 2002-08-29
WO2001026603A2 (en) 2001-04-19
EE200200103A (et) 2003-04-15
EA200200284A1 (ru) 2002-10-31
AR025455A1 (es) 2002-11-27
NZ517470A (en) 2004-03-26
PE20010579A1 (es) 2001-06-04
SI20853A (sl) 2002-10-31
UA77150C2 (en) 2006-11-15
CZ2002707A3 (cs) 2002-11-13
KR20020038745A (ko) 2002-05-23
LT5001B (lt) 2003-03-25
NO20020998L (no) 2002-03-14
BR0013711A (pt) 2002-05-07
NO20020998D0 (no) 2002-02-28
EA006805B1 (ru) 2006-04-28
HRP20020265A2 (en) 2004-02-29
SK2982002A3 (en) 2002-07-02
AU3215001A (en) 2001-04-23
JP2003511399A (ja) 2003-03-25
CA2383650A1 (en) 2001-04-19
HUP0202515A3 (en) 2004-06-28
HUP0202515A2 (hu) 2002-12-28
EP1605949A2 (en) 2005-12-21
MXPA02002186A (es) 2002-09-02
WO2001026603A3 (en) 2002-01-17
BG106441A (bg) 2002-09-30
CN1384748A (zh) 2002-12-11
AU781835B2 (en) 2005-06-16
IL148415A0 (en) 2002-09-12
YU13902A (sh) 2006-01-16
LV12940B (en) 2003-06-20

Similar Documents

Publication Publication Date Title
WO1995011013A3 (de) Kombination von progesteronantagonisten und antiöstrogenen mit partialer agonistischer wirkung für die hormonsubstitutions-therapie für peri- und postmenopausale frauen
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
HUP0103345A3 (en) Use of estrogen receptor modulators in combination with sexual steroid precursors for the preparation of pharmaceutical compositions
WO2004110408A3 (en) Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol
PT836506E (pt) Penso transdermico para administracao de 17-desacetil norgestimato so ou em combinacao com um estrogenio
WO2002047693A3 (en) Steroid hormone products comprising a stabilizing agent in non-crystalline form
CA2188907A1 (en) Combination compound for contraception based on natural estrogen
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
WO2000042942A3 (en) Buccal drug delivery system for use in male contraception
LT2002035A (lt) Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip moterų kontraceptikų komponentas
WO2000074649A3 (en) Ophthalmic histamine compositions and uses thereof
YU14002A (sh) Mezoprogestini (progesteron receptor modulatori) za lečenje i prevenciju benignih hormonskih ginekoloških poremećaja
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
EP1090639A3 (en) Pharmaceutical composition containing a progestational corticoid and a selective estrogen receptor modulator
HUP0203721A2 (hu) Új hormonkészítmény és alkalmazása
WO1999020223A3 (en) Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
EA200601089A1 (ru) Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение
WO2001034126A3 (en) Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
MXPA01011296A (es) Composiciones contraceptivas que contienen derivados de indolina y agentes progestacionales.
WO2003099322A3 (en) Il-11 derivatives and therapeutic uses thereof
WO1996028154A3 (de) Verwendung von antiestrogenen zur männlichen fertilitätskontrolle
TW200640468A (en) Pharmaceutical product for oral contraception
Robb-Nicholson By the way, doctor. I am 47 and have been taking Loestrin 1/20 for the past seven months. After the first month, I ceased having periods, which my gynecologist says is typical. Could you comment on why this happens and whether I am putting myself at increased risk for uterine cancer?
IL125983A0 (en) Pharmaceutical composition comprising factor xiiia

Legal Events

Date Code Title Description
PC9A Transfer of patents

Owner name: SCHERING AKTIENGESELLSCHAFT, DE

Effective date: 20030513

MM9A Lapsed patents

Effective date: 20080831